CoChat
Sign Up
Cited by 23

The DOI matches its Crossref record.

Increased Eps15 homology domain 1 and RAB11FIP3 expression regulate breast cancer progression via promoting epithelial growth factor receptor recycling

Tong, Dandan, Liang, Ya-Nan, Stepanova, AA, Liu, Yu, Li, Xiaobo, Wang, Letian, Zhang, Fengmin, Vasilyeva, NV·2017·Tumor Biology
DOI 10.1177/1010428317691010
Open this paper in CoChat — free account

Abstract

Recent research indicates that the C-terminal Eps15 homology domain 1 is associated with epithelial growth factor receptor–mediated endocytosis recycling in non-small-cell lung cancer. The aim of this study was to determine the clinical significance of Eps15 homology domain 1 gene expression in relation to phosphorylation of epithelial growth factor receptor expression in patients with breast cancer. Primary breast cancer samples from 306 patients were analyzed for Eps15 homology domain 1, RAB11FIP3, and phosphorylation of epithelial growth factor receptor expression via immunohistochemistry. The clinical significance was assessed via a multivariate Cox regression analysis, Kaplan–Meier curves, and the log-rank test. Eps15 homology domain 1 and phosphorylation of epithelial growth factor receptor were upregulated in 60.46% (185/306) and 53.92% (165/306) of tumor tissues, respectively, as assessed by immunohistochemistry. The statistical correlation analysis indicated that Eps15 homology domain 1 overexpression was positively correlated with the increases in phosphorylation of epithelial growth factor receptor ( r = 0.242, p < 0.001) and RAB11FIP3 ( r = 0.165, p = 0.005) expression. The multivariate Cox proportional hazard model analysis demonstrated that the expression of Eps15 homology domain 1 alone is a significant prognostic marker of breast cancer for the overall survival in the total, chemotherapy, and human epidermal growth factor receptor 2 (−) groups. However, the use of combined expression of Eps15 homology domain 1 and phosphorylation of epithelial growth factor receptor markers is more effective for the disease-free survival in the overall population, chemotherapy, and human epidermal growth factor receptor 2 (−) groups. Moreover, the combined markers are also significant prognostic markers of breast cancer in the human epidermal growth factor receptor 2 (+), estrogen receptor (+), and estrogen receptor (−) groups. Eps15 homology domain 1 has a tumor suppressor function, and the combined marker of Eps15 homology domain 1/phosphorylation of epithelial growth factor receptor expression was identified as a better prognostic marker in breast cancer diagnosis. Furthermore, RAB11FIP3 combines with Eps15 homology domain 1 to promote the endocytosis recycling of phosphorylation of epithelial growth factor receptor.

Overview

Integrity signals

Registry

Crossref · 10.1177/1010428317691010

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In breast cancer, EHD1-positive patients have shorter overall and disease-free survival, and EHD1-positive plus phospho-EGFR-positive status is even more predictive of shorter survival.

    “EHD1-positive (EHD1+) patients had a shorter overall and disease-free survival, and a patient status of EHD1+ plus phospho-EGFR+ was even more predictive of shorter survival (45).”

    From EHD1 and RUSC2 Control Basal Epidermal Growth Factor Receptor Cell Surface Expression and Recycling (2020) · cites this paper as [45]

  • In breast cancer, EHD1 and RAB11-FIP3 expression positively correlate, and these markers correlate with phospho-EGFR levels in tumors.

    “A similar analysis in breast cancer showed a positive correlation between EHD1 and RAB11-FIP3 expression, and the expression of these markers correlated with phospho-EGFR levels in tumors;”

    From EHD1 and RUSC2 Control Basal Epidermal Growth Factor Receptor Cell Surface Expression and Recycling (2020) · cites this paper as [45]

  • EHD1 expression is associated with poor prognosis in non-small cell lung cancer and breast cancer.

    “EHD1 expression was recently found to be associated with poor prognosis in non-small cell lung cancer (43, 44) and breast cancer (45), and EHD1 levels in NSCLC showed a negative correlation with sensitivity to EGFR-targeted kinase inhibitor therapy (47).”

    From EHD1 and RUSC2 Control Basal Epidermal Growth Factor Receptor Cell Surface Expression and Recycling (2020) · cites this paper as [45]

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 37

  1. 10.1093/jnci/dji289 · DOI
  2. 10.1158/1078-0432.CCR-04-0220 · DOI
  3. 10.1097/PPO.0b013e3181d24fc1 · DOI
  4. 10.1158/0008-5472.CAN-15-2478 · DOI
  5. Sebastian S, 2006, Biochim Biophys Acta, 1766, 120
  6. 10.1038/nrm1315 · DOI · Paper page
  7. 10.1038/nrc2088 · DOI · Paper page
  8. 10.1128/MCB.02356-05 · DOI
  9. 10.1126/science.1101637 · DOI
  10. 10.1128/MCB.13.9.5814 · DOI
  11. 10.1242/jcs.120196 · DOI
  12. 10.1073/pnas.92.21.9530 · DOI
  13. 10.4161/psb.6708 · DOI
  14. 10.4161/cib.2.5.8931 · DOI
  15. 10.1016/j.bbrc.2004.04.157 · DOI
  16. 10.1074/jbc.M108665200 · DOI
  17. 10.1111/j.1600-0854.2008.00834.x · DOI · Paper page
  18. 10.1093/emboj/21.11.2557 · DOI · Paper page
  19. 10.1016/j.tplants.2007.09.001 · DOI
  20. 10.1111/j.1600-0854.2005.00359.x · DOI · Paper page
  21. 10.1111/j.1365-313X.2008.03571.x · DOI
  22. 10.1007/s13277-014-2164-x · DOI · Paper page
  23. 10.1186/1471-2121-10-84 · DOI · Paper page
  24. 10.1074/jbc.M104831200 · DOI
  25. 10.1016/S0006-291X(02)02720-1 · DOI · Paper page
  26. 10.1091/mbc.e04-10-0927 · DOI
  27. 10.1038/sj.emboj.7600803 · DOI
  28. 10.1111/j.1600-0854.2007.00543.x · DOI
  29. 10.1677/erc.1.01032 · DOI
  30. 10.1152/ajpgi.00118.2013 · DOI
  31. 10.1590/1414-431X20144099 · DOI
  32. 10.5306/wjco.v5.i5.806 · DOI
  33. Meng Q, 2016, Oncotarget, 8
  34. 10.1083/jcb.135.4.913 · DOI · Paper page
  35. 10.1091/mbc.e05-05-0466 · DOI · Paper page
  36. Wang B, 2014, Zhonghua Zhong Liu Za Zhi, 36, 273
  37. 10.1186/1746-1596-9-118 · DOI

Cited by

Sorted by citations

Metadata

Authors
Tong, D., Liang, Y.-N., Stepanova, A., Liu, Y., Li, X., Wang, L., Zhang, F., & Vasilyeva, N.
Affiliations
  • Department of Pathology, Harbin Medical University, Harbin, China
  • Kashkin Research Institute of Medical Mycology, I.I. Mechnikov North-Western State Medical University, Saint Petersburg, Russia
  • College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China
Venue
Tumor Biology
Publisher
SAGE Publications
Published
2017-02
Volume
39
Issue
2
ISSN
  • 1010-4283
  • 1423-0380
DOI
10.1177/1010428317691010
Cited by
23
References
0
Language
en
Licence
creativecommons.org/licenses/by-nc/3.0/ (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review